HK1124083A1 - Human circulating virus inhibitory peptide (vrip) and its use (virip) - Google Patents

Human circulating virus inhibitory peptide (vrip) and its use (virip)

Info

Publication number
HK1124083A1
HK1124083A1 HK08113441.0A HK08113441A HK1124083A1 HK 1124083 A1 HK1124083 A1 HK 1124083A1 HK 08113441 A HK08113441 A HK 08113441A HK 1124083 A1 HK1124083 A1 HK 1124083A1
Authority
HK
Hong Kong
Prior art keywords
virip
virus
activity
antagonist
inhibitor
Prior art date
Application number
HK08113441.0A
Other languages
English (en)
Chinese (zh)
Inventor
Frank Kirchhoff
Jan Mnch
Ludger Stndker
Wolf-Georg Forssmann
Knut Adermann
Original Assignee
Ipf Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999153732 external-priority patent/DE19953732A1/de
Priority claimed from DE2000123665 external-priority patent/DE10023665A1/de
Application filed by Ipf Pharmaceuticals Gmbh filed Critical Ipf Pharmaceuticals Gmbh
Publication of HK1124083A1 publication Critical patent/HK1124083A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
HK08113441.0A 1999-11-08 2008-12-10 Human circulating virus inhibitory peptide (vrip) and its use (virip) HK1124083A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999153732 DE19953732A1 (de) 1999-11-08 1999-11-08 Humanes zirkulierendes Virus inhibierendes Peptid (VIRIP) und seine Verwendung
DE2000123665 DE10023665A1 (de) 2000-05-16 2000-05-16 Humanes zirkulierendes Virus inhibierendes Peptid (VIRIP) und seine Verwendung

Publications (1)

Publication Number Publication Date
HK1124083A1 true HK1124083A1 (en) 2009-07-03

Family

ID=26005679

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113441.0A HK1124083A1 (en) 1999-11-08 2008-12-10 Human circulating virus inhibitory peptide (vrip) and its use (virip)

Country Status (13)

Country Link
US (1) US7037896B1 (fr)
EP (2) EP1959013B1 (fr)
JP (1) JP4813720B2 (fr)
AT (1) ATE398674T1 (fr)
AU (1) AU2354801A (fr)
CA (1) CA2390652C (fr)
CY (1) CY1108330T1 (fr)
DE (1) DE50015216D1 (fr)
DK (1) DK1228203T3 (fr)
ES (1) ES2307549T3 (fr)
HK (1) HK1124083A1 (fr)
PT (1) PT1228203E (fr)
WO (1) WO2001034640A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100144630A1 (en) * 1999-03-05 2010-06-10 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
US20100210528A1 (en) * 1999-03-05 2010-08-19 Leland Shapiro Compositions, methods and uses for inhibition and/or treatment of influenza infection
EP1572743B1 (fr) 2002-12-19 2011-08-10 IPF Pharmaceuticals GmbH Peptides et leur utilisation pour le traitement d'une infection par vih
EP1756160B1 (fr) * 2004-06-18 2013-08-14 IPF Pharmaceuticals GmbH Peptides oligomeres et leur utilisation pour traiter des infections a vih
EP2025762A3 (fr) 2006-01-17 2009-09-30 Health Research Inc. Analyse de suivi hétéroduplex
CN102507824B (zh) * 2011-11-01 2013-10-09 北京三元基因工程有限公司 聚乙二醇修饰蛋白质的修饰位点分析方法
EP3473650A1 (fr) * 2017-10-18 2019-04-24 Universitätsklinikum Jena Anticorps pour la détection spécifique de fragments de caap47/48
JP2023511073A (ja) * 2020-01-16 2023-03-16 ケース ウエスタン リザーブ ユニバーシティ 好中球エラスターゼ結合ペプチドおよびその組成物
EP4232460A1 (fr) * 2020-10-22 2023-08-30 The University of Hong Kong Compositions de peptides et/ou de composés antiviraux et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1303530C (fr) * 1983-01-21 1992-06-16 Michael Courtney VECTEURS D'EXPRESSION ET LEUR UTILISATION POUR LA PREPARATION D'UNE PROTEINE AYANT UNE ACTIVITE .alpha. -ANTITRYPSINE HUMAINE
US5827662A (en) 1989-06-23 1998-10-27 The Trustees Of The University Of Pennsylvania Methods for detecting genetic mutations resulting in protease inhibitor insufficiencies
CA2108689A1 (fr) 1991-04-18 1992-10-19 Edward J. Miller Compositions et methodes pour l'inhibition de l'elastase
US5175253A (en) 1991-04-24 1992-12-29 Washington University Binding peptides
US5972901A (en) * 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
CA2391348A1 (fr) 1999-07-29 2001-02-08 Assem Ziady Administration amelioree par l'intermediaire d'un recepteur du complexe enzyme inhibiteur de la serine protease

Also Published As

Publication number Publication date
CA2390652A1 (fr) 2001-05-17
DE50015216D1 (de) 2008-07-31
CA2390652C (fr) 2011-03-29
US7037896B1 (en) 2006-05-02
JP2003516729A (ja) 2003-05-20
ES2307549T3 (es) 2008-12-01
EP1228203B1 (fr) 2008-06-18
WO2001034640A2 (fr) 2001-05-17
EP1228203A2 (fr) 2002-08-07
CY1108330T1 (el) 2014-02-12
WO2001034640A3 (fr) 2001-11-01
DK1228203T3 (da) 2008-10-20
PT1228203E (pt) 2008-09-03
ATE398674T1 (de) 2008-07-15
EP1959013B1 (fr) 2014-04-23
EP1959013A1 (fr) 2008-08-20
JP4813720B2 (ja) 2011-11-09
AU2354801A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
HK1124083A1 (en) Human circulating virus inhibitory peptide (vrip) and its use (virip)
Bodenmüller et al. Conserved amino acid sequence of a neuropeptide, the head activator, from coelenterates to humans
EP0665754B1 (fr) Peptides antimicrobiens
AU756014B2 (en) Delivery system
EP2049562B1 (fr) Peptides ayant une activité pharmacologique pour le traitement de troubles associés à la migration de cellules altérées, tels que le cancer
HUT75058A (en) Amplification of the vitamin b12 uptake system using polymers
EP1037657A4 (fr) Conjugues d'inteferon-alpha-polymere a activite biologique accrue et leurs methodes de preparation
WO2000007543A2 (fr) Conjugues cibles apportes aux recepteurs cibles et/ou aux recepteurs de l'interleukine 2
CN110621349A (zh) 甲氨蝶呤和肽的偶联物
CN1781933B (zh) 胸腺素α1活性片段环肽类似物及其聚乙二醇化衍生物
US8026207B2 (en) Peptides and compositions for inhibiting fungal growth
Rastogi et al. Augmentation of human natural killer cells by splenopentin analogs
KR102160566B1 (ko) 미녹시딜과 펩타이드의 결합체
EP0858808B1 (fr) Peptides applicables au traitement de lésions
Maeda et al. Amino Acids and Peptides: XXXIII. A Bifunctional Poly (ethylene Glycol) Hybrid of Laminin-Related Peptides
AU667290B2 (en) Peptides that block human immunodeficiency virus infections and methods of use thereof
Fiedler PIG PANCREATIC KALLIKREIN: STRUCTURE AND CATALYTIC PROPERTIES¹
JP3726106B2 (ja) アンジオテンシン変換酵素阻害剤及び血圧降下剤
Birr Synthetic small thymic peptides: an immunoregulatory concept
EP0532716B1 (fr) Nouveaux peptides synthetiques ayant une activite imunomodulatrice et leur preparation
JP3546231B2 (ja) 新規ペプチド、及び該ペプチドを用いた組成物
IL150045A0 (en) Compositions and methods for detecting stress-inducible proteins
BR112021008797A2 (pt) Polipeptídeos para o tratamento de síndromes de estresse, imunorreação e derrame
CA2398395A1 (fr) Conjugues cibles sur des recepteurs cibles
Naider et al. Inhibition of oligopeptide transport in S. cerevisiae by a peptide-poly (ethylene glycol) conjugate

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181105